Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$2.2B
63M shares
52-week range
$3.60 – $47.84
77% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Borrow rate
0.41%
Easy to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $490.0K | $911.0K | $4.2M | $8.7M | $11.0M | $25.9M | $26.7M | $0 |
| Gross profit | −$490.0K | −$911.0K | −$4.2M | −$8.7M | −$11.0M | −$25.9M | −$26.7M | $0 |
| Gross margin | — | — | — | — | — | — | — | — |
| R&D | $18.8M | $37.5M | $107.4M | $217.3M | $267.6M | $206.3M | $126.1M | $182.4M |
| Operating income | −$26.4M | −$49.2M | −$136.0M | −$267.1M | −$341.4M | −$277.3M | −$186.8M | −$234.4M |
| EBITDA | −$35.4M | −$46.4M | −$128.9M | −$258.3M | −$322.8M | −$234.5M | −$149.5M | −$203.6M |
| Net income | −$41.4M | −$47.4M | −$133.1M | −$267.0M | −$333.8M | −$260.5M | −$176.2M | −$230.0M |
| Net margin | — | — | — | — | — | — | — | — |
| EPS (diluted) | -1.16 | -1.23 | -2.91 | -5.16 | -6.39 | -4.97 | -3.35 | -4.32 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $11M | $-3.74 | $-4.16–$-3.35 | 5 |
| 2027 | $46M | $-3.12 | $-3.53–$-2.72 | 4 |
| 2028 | $236M | $-0.86 | $-1.74–$-0.39 | 3 |
| 2029 | $498M | $1.17 | $0.26–$1.84 | 1 |
Forward consensus · source: Financial Modeling Prep
Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.
www.kodiak.comNo one on the platform currently holds KOD.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 294,300 | $11.2M |
No one on the platform has traded KOD yet.
| $2.1B |
| — |
| OCSOculis Holding AG | $13.09 | +9.08% | $748M | — |
| PHATPhathom Pharmaceuticals, Inc. | $10.87 | +1.40% | $867M | — |
Source: Financial Modeling Prep · peers by sector/industry
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$KOD the issue is daybreak readout is very risky imo, GLOW 2 was like a 90% probability of success. This is the major overhang, Will it win over eyela?
View on StockTwits ↗$KOD no reason for drop, people undervaluing duration and improved safety imo
View on StockTwits ↗$KOD massive dump today. probably more tomorrow. can we see under $30 again?
View on StockTwits ↗$KOD starting to recover from the profit taking after the initial hype from the March results. hoping we are now heading to maybe $50 range over next few months in anticipation of the September results? What do we think?
View on StockTwits ↗$OCUL getting perky 💪💪. Reminds me of the good old days with $KOD
View on StockTwits ↗$MLTX trades at meaningfully lower multiples of analyst consensus versus 6 peers with near term Phase 3 data reads. $DFTX reported solid Phase 3 data as well. Note: Share price & market cap are intra-day 6/22/26. We Googled "Sonelokimab patent expiration" & the results suggested MLTX's IP is good thru FY40 yet analyst consensus drops in FY35 from FY34. Any guidance on MLTX would be appreciated? We thought MLTX reported disappointing data at the end of Q325. $IRON & $AMLX trade at the highest multiples in this peer group. $KOD trades at the 2nd lowest multiple in this specific peer group.
View on StockTwits ↗@DidYouReadThis $KOD will rock it as well this year, save it for later..
View on StockTwits ↗$KOD not sure how reliable this is ? https://www.forbes.com/sites/greatspeculations/2026/03/30/kodiak-sciences-road-to-120/
View on StockTwits ↗@KoalaFlipper hey bro, nice post, my black horses are $OTLK $NRSN and $KOD
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.